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Heparan sulfate proteoglycans (HSPGs) are common constituents of
cell surfaces and the extracellular matrix (ECM), including basement
membranes (see Bernfield et al, 1999; Gallagher and Lyon, 2000 for
reviews). There is now ample evidence that HSPGs are essential for
normal cell growth and development. This came initially from
biochemical and cell culture studies that suggested a key co-receptor
function for HSPGs in mediating cell responses to growth factors and
chemokines. More recently, genetic studies in Drosophila and mice
(Selleck, 2000) and identification of the genes responsible for two
inherited diseases in man, the Simpson Golabi Behmel syndrome
(SGBS) and hereditary multipleexostoses (HME), have demon-
strated that alterations in HSPG synthesis lead to phenotypic changes
indicative of aberrant control of cell growth, differentiation, organo-
genesis, and bone formation. In addition, a tumour suppressor func-
tion has been attributed to the genes causing SGBS and HME
because affected individuals are at increased risk of cancer. 
HEPARAN SULFATE PROTEOGLYCANS AND
CELL REGULATION 
HSPGs comprise a protein core to which chains of the glycosamino-
glycan (GAG), heparan sulfate (HS) are covalently attached during
post-translational modification (Figure 1). At the cell surface, the
two major families of HSPG are the transmembrane syndecans (S)
and the GPI-anchored glypicans (Gpc) (Bernfield et al, 1999). The
HSPGs found in the ECM (perlecan, agrin, collagen XVIII) are
large modular proteins, that contribute to the structure, hydration
and permeability of the matrix. Functions attributed to both cell
membrane and ECM HSPGs are varied. They sequester growth
factors and provide protection from proteolytic degradation,
enhance formation of receptor–ligand signalling complexes and
direct ligands into the cell for degradation or recycling (see
Bernfield et al, 1999; Gallagher and Lyon, 2000). The significance
of HSPGs in cell regulation is further emphasised by the presence of
HS-binding domains in cell adhesion proteins of the ECM, such as
fibronectin. The concerted action of cell surface integrins and
HSPGs (specifically the syndecans) direct cell attachment to these
ECM substrates, leading to the formation of focal adhesions
(Bernfield et al, 1999 and references therein). The capacity of
HSPGs to interact with both the matrix architecture and soluble
ligands (Table 1) defines a unique combination of properties that
enables normal cells to sense, and respond to, controlling influences
in their environment. Cancer cells employ various mechanisms to
exploit these properties and gain a survival advantage. 
HSPGs IN CANCER 
Altered HSPG expression 
HSPG expression is developmentally regulated and altered in
various pathophysiological processes, including cancer. The
expression patterns are believed to mirror those of ligands that
require HSPGs to elicit their cellular responses. For example,
Glypican 1 expression is up-regulated in pancreatic cancer cells
and surrounding fibroblasts, and the mitogenic response of pancre-
atic cancer cells to bFGF and HB-epidermal growth factor is abro-
gated by anti-sense attenuation of this HSPG (Kleef et al, 1998).
Similarly, perlecan expression is up-regulated at sites of active
angiogenesis, and the angiogenic affects of bFGF are suppressed
by experimental down-regulation of perlecan (Sharma et al, 1998). 
HSPG catabolism yields bioactive products 
The breakdown products of HSPGs exhibit distinct physiological
roles. Syndecans are shed from the cell surface as soluble mole-
cules (ectodomains) that regulate protease and GF activity.
For example, in contrast to their cell surface precursors, S1
ectodomains inhibit bFGF signalling (Bernfield et al, 1999). This
change in function is believed to ‘fine tune’ GFs recruited for
Review
Heparan sulfate proteoglycans and cancer 
FH Blackhall, CLR Merry, EJ Davies and GC Jayson 
Cancer Research Campaign Department of Medical Oncology, Christie Hospital and Paterson Institute for Cancer Research, Wilmslow Road, Withington,
Manchester M20 4BX, UK 
Summary Heparan sulfate proteoglycans (HSPGs) are widely distributed in mammalian tissues and involved in a number of processes
related to malignancy. They are composed of a core protein to which chains of the glycosaminoglycan, heparan sulfate (HS), are attached.
The existence of various classes of core protein, in addition to highly polymorphic HS chains, creates a superfamily of macromolecules with
considerable diversity of structure and function. HSPGs interact with many proteins including growth factors, chemokines and structural
proteins of the extracellular matrix to influence cell growth, differentiation, and the cellular response to the environment. The recent
identification of two inherited syndromes that are associated with an increased cancer risk, and caused by mutations in HSPG-related genes,
has intensified interest in these molecules. This review describes our current understanding of HSPGs in cancer and highlights new
possibilities for therapeutic control. © 2001 Cancer Research Campaign http://www.bjcancer.com 
Keywords: heparan sulfate; proteoglycans; cancer 
1094
Received 6 February 2001 
Revised 25 June 2001 
Accepted 29 June 2001 
Correspondence to: FH Blackhall 
British Journal of Cancer (2001) 85(8), 1094–1098
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2054, available online at http://www.idealibrary.com on  http://www.bjcancer.comHeparan sulfate proteoglycans 1095
British Journal of Cancer (2001) 85(8), 1094–1098 © 2001 Cancer Research Campaign
tissue repair and remodelling. Enhanced shedding of S1 is
observed in cancer but its role is poorly understood (Stanley et al,
1999). An intriguing property of S1 ectodomains is that they
inhibit growth of various cancer cell lines in vitro and S1
ectodomains shed from myeloma cells induce apoptosis of
myeloma allografts in SCID mice (Dhodapkar et al, 1998). In clin-
ical studies of multiple myeloma serum S1 is an independent prog-
nostic indicator with ‘high’ levels conferring an adverse prognosis
(Seidel et al, 2000). 
Heparanase mediates angiogenesis, tumour invasion
and metastasis 
The heparanase enzymes degrade HS chains and are believed to
play a major role in tumour progression. They are present in
multiple normal and malignant cell types, but have proved particu-
larly difficult to characterise. A range of molecular weights for
heparanase has been reported, suggesting a family of distinct
enzymes. This theory was initially challenged by the recent cloning
of a single heparanase gene (HPA1) encoding identical enzymes in
human hepatoma, placenta and platelets (Vlodavsky et al, 1999).
However, a second gene (HPA2) with significant homology to
HPA1, that gives rise to 3 proteins by alternative splicing has subse-
quently been reported (McKenzie et al, 2000). Their functions have
not been fully characterised but, interestingly, the tissue distribution
and cellular localisation of HPA2 appears distinct from HPA1
suggesting different roles in HS catabolism. 
In experimental models of cancer increased heparanase produc-
tion correlates with enhanced metastatic potential. Heparanase
activity has also been detected in the sera and urine of cancer
patients although the prognostic/diagnostic significance of this has
not been determined (Vlodavsky et al, 1999). Proteases (such as
the MMPs) and heparanases are believed to cooperate in the
degradation of the ECM and basement membranes. Interestingly,
heparanase reverses the inhibitory activity of shed S1 ectodomains
by liberating fragments of HS that activate bFGF (Bernfield et al,
1999). In contrast to the MMPs, only a few heparanases have been
identified to date, suggesting that heparanase may be particularly
amenable to therapeutic manipulation. Cancer cells can therefore
manipulate HSPGs via various mechanisms. In addition, for some
HSPGs a tumour suppressor (TSP) role has been proposed. 
A novel family of tumour suppressors? 
In experimental studies of malignant transformation, S1 expres-
sion is associated with maintenance of epithelial morphology,
anchorage-dependent growth and inhibition of invasiveness (see
Inki and Jalkanen 1996 for review). S1 is down-regulated in many
epithelial cancers and in premalignant lesions of the oral mucosa
and uterine cervix, its loss is an early genetic event contributing to
tumour progression. Loss of S1 also correlates with reduced
survival in squamous cell carcinoma of the head and neck, laryn-
geal cancer (Inki and Jalkanen, 1996) and malignant mesothe-
lioma (Kumar-Singh et al, 1998); and higher metastatic potential
in hepatocellular cancer (Matsumoto et al, 1997). 
However, S1 also exhibits tumour promoter function. For
example, S1 is essential for wnt-1 induced tumorigenesis of the
mouse mammary gland (Alexander et al, 2000) and promotes
formation of metastases in mouse lung squamous carcinoma cells
(Hirabayashi et al, 1998). Enhanced S1 expression is observed in
pancreatic cancer (Conejo et al, 2000) and the most invasive cells
in ovarian cancer (J Davies–unpublished observation). This ‘dual
role’ of S1 may reflect tissue-specific HSPG function. There is
evidence for this in Drosophila, where the glypican homologue
dally selectively participates with several GF signalling pathways
in a tissue specific manner (Selleck, 2000 for review). The rare
Simpson–Golabi–Behmel syndrome (SGBS) provides compelling
evidence that an HSPG can function as a tumour suppressor. 
Glypican 3 – a negative regulator of cell growth 
SGBS is an X-linked syndrome characterised by pre- and post-natal
overgrowth and an increased frequency of embryonal tumours such
as Wilm’s tumour of the kidney and neuroblastoma. Affected males
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Figure 1 Classification and structure of HSPGs. 4 mammalian syndecan
isoforms (S1–4) are encoded by separate genes. These transmembrane
proteins adopt highly extended conformations, have short cytoplasmic tails
and HS attachment sites are clustered near the N-terminus in the
ecotodomain. S1, 2 and 4 also carry chondroitin sulfate (CS) side chains in
addition to HS. The syndecan core proteins are least homologous in the
ectodomains although the HS attachment sites are highly conserved.
Discrete genes have been described for 6 glypican core proteins (Gpc1–6).
These core proteins are extracellular globular glycoproteins that attach to the
cell membrane via a glycosylphosphatidylinositol (GPI) anchor and HS
chains are positioned close to the cell membrane. The ECM-resident
perlecan comprises a large multidomain, 400 kD core protein to which
several HS chains attach to a terminal globule 
Table 1 Heparin-binding proteins of the tumour microenvironment 
Antithrombin III 
Collagens 
Elastase 
Endostatin 
Fibroblast growth factors including bFGF, aFGF, KGF 
Fibrin 
Fibronectin 
Granulocyte-macrophage colony stimulating factor 
Hepatocyte growth factor/scatter factor 
Heparin-binding epidermal growth factor (HB-EGF) 
Hyaluronidase 
Insulin-like growth factors 
Interferon-γ
Interleukin 3,8 
Laminin 
L-selectin 
Midkine 
Neural cell adhesion molecule 
Platelet-derived growth factor 
Platelet factor 4 
Superoxide dismutase 
Thrombospondin 
Transforming growth factor β
Tumour necrosis factor 
Urokinase 
Vascular endothelial cell growth factor 
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can reach heights of two metres and often exhibit features including
congenital heart defects and dysplastic kidneys. The syndrome is
caused by mutation of the glypican 3 gene (GPC3) (Pilia et al,
1996) and is the first inherited disorder known to involve an HSPG.
The developmental abnormalities associated with SGBS provide
confirmation that GPC3 is a critical regulator of tissue growth and
morphogenesis. It is believed that defects in GF signalling path-
ways due to loss of function of GPC3 (Veugelers et al, 2000)
account for the abnormalities in SGBS, and possible candidates
include insulin-like growth factor 2 (Pilia et al, 1996) and bone
morphogenetic protein 4 (Paine-Saunders et al, 2000). 
A TSP role for GPC3 has been proposed due to the incidence of
embryonal tumours in SGBS, and the ability of GPC3 to induce
cell-line-specific apoptosis in rat metastatic melanoma and human
breast cancer MCF7 cells (Gonzalez et al, 1998). The mechanism
of apoptosis is unclear, but is independent of glycosylation which,
uncharacteristically for an HSPG (see next section), suggests
a direct interaction between a ligand and the core protein rather
than the HS chain. Location of a TSP on the X chromosome is
intriguing since men, with only one copy, would be more vulner-
able to tumour formation. However, GPC3 expression becomes
restricted to the ovary and colon in adult tissues, and GPC3 may
act as a negative regulator of growth exclusive to female tissues
such as the ovary in vivo (Lin et al, 1999). Indeed, the chromo-
somal region encompassing the GPC3 gene on Xq26 is deleted in
approximately 30% of patients with sporadic ovarian cancer (Choi
et al, 1997). Correspondingly, in a screen of ovarian cancer cell
lines employing a candidate gene approach, no GPC3 mutations
were identified, but transcriptional silencing by hypermethylation
of the GPC3 promoter was detected in 30% of cell lines (Lin et al,
1999). Interestingly, the same mechanism (of loss) has been identi-
fied in a proportion of rat and human malignant mesothelioma cell
lines and tumours (Murthy et al, 2000). Consistent with a TSP role,
ectopic transfection of GPC3 inhibits cell growth in ovarian cancer
cells that have lost endogenous GPC3 expression (Lin et al, 1999). 
Glycosylation – a major determinant of HSPG function 
The ability of HSPGs to bind with high specificity to a wide range of
diverse ligands is rooted in the structure of the HS chains (Gallagher
and Lyon, 2000). A complicated biosynthetic machinery, that is not
yet fully understood, enables cells to glycosylate core proteins for
their own ligand-binding requirements (Figure 2). Mature HS is
composed of hypervariable sulfated domains (S-domains) separated
by regions of low sulfation (N-acetylated regions). This unique
molecular design encodes specific recognition sites for multiple HB
ligands. For example, antithrombin III recognises a unique pentasac-
charide sequence containing a rare glucosamine 3-O-sulfate
(Lindahl et al, 1998). This sequence is the basis for the clinical effi-
cacy of the anticoagulant heparin and is thought to occur in the
boundary between an S-domain and N-acetylated region. In
contrast, bFGF binds with high affinity to S-domains characterised
by a repeating disaccharide sequence [IdoA2S-GlcNS]5 (Gallagher
and Lyon, 2000). However, the additional presence of 6-O-sulfated
GlcNS within this sequence is necessary for activation of bFGF. In
turn, sequences that lack 6-O-sulfation are inhibitory and the cellular
response to bFGF in vivo may ultimately depend on the balance of
sequence presented (Pye et al, 1998). Although heparin is often used
experimentally as a surrogate for HS, it lacks both the structural
complexity and the N-acetylated regions. The function of these
regions in vivo is uncertain but is likely to include the presentation
of S-domains in the correct orientation to dimeric and oligomeric
ligands such as platelet factor 4 and transforming growth factor β
that bind more than one S-domain simultaneously (Lyon and
Gallagher, 2000). 
The controlled variability of HS biosynthesis that is vital for the
co-ordination of appropriate responses to pericellular ligands, may
also be ‘hijacked’ by cancer cells. Structural alterations of HS are
observed in various cell models of transformation (Jayson et al,
1998), lung cancer (Nackaerts et al, 1997) and human primary
liver tumour sections (Matsumoto et al, 1997). Hereditary multiple
exostosis (HME) provides the first direct evidence linking aberrant
HS structure to tumorigenesis. 
Heparan sulfate biosynthesis and cancer 
HME is an autosomal dominant disorder (estimated frequency 1:50
000) characterised by the presence of multiple bony outgrowths
(exostoses) arising from the juxtaepiphyseal regions of long bones
(Figure 3). The initial application of genetic linkage to HME families
revealed this to be a multigenic disorder with 3 loci on chromosomes
8q24 (EXT1), 11p11-13 (EXT2) and 19p (EXT3). The phenotype of
HME is identical for each locus, with the majority of cases attributed
to mutations in EXT1 and 2. Additional gene family members not yet
associated with disease include 3 EXT-like genes (EXTL1,
EXTL2/EXTR2, EXTL3/EXTR1) (see Stickens and Evans, 1998 for
review). In at least 2% of HME patients, exostoses undergo malig-
nant transformation into chondrosarcomas or osteosarcomas
(Hennekam, 1991). Both sporadic and exostosis-derived chondrosar-
comas show loss of allelic heterozygosity for markers around the
EXT 1 and EXT 2 loci suggesting a tumour suppressor (TSP) gene
model (Hecht et al, 1995; Raskind et al, 1995). 
The functions of EXT family members were discovered by
chance during investigations of genes involved in GAG biosynthesis
and could not have been anticipated (McCormick et al, 1998). EXT1
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Figure 2 A simplified scheme of heparan sulfate synthesis (see Lindahl
1998 for review). Heparan polymers comprise 50–200 N-acetylglucosamine-
glucuronic acid (GlcNAc α 1, 4 GlcA) repeats attached to core proteins at
Ser-Gly repeat sequences. Transformation of heparan to HS is initiated by
the N-deacetylase/N-sulfotransferase (NDST) enzymes, that modify a
proportion (usually 40–50%) of GlcNAc to N-sulfoglucosamine (GlcNS). 
This, and the following modifications are non-random, interdependent and
quantitatively incomplete. Uronate epimerase converts GlcA adjacent to
GlcNS to the C-5 epimer, iduronate (IdoA). O-sulfotransferases act on
resulting GlcNS/IdoA rich domains, beginning with HS-2OST which 
transfers sulfate to C-2 of the IdoA residues. Subsequently, 6-O and 3-O
sulfotransferases (6- and 3-OSTs) complete the heparan-HS transition by
transferring sulfate groups to C-6 or C-3 of the amino sugars. Members of
the gene families recognise subtly different disaccharide substrates to create
microstructurally heterogeneous sulfated (S) domains Heparan sulfate proteoglycans 1097
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and EXT2, encode an enzyme (GlcA/GlcNAc transferase) required
for chain elongation and synthesis of HS (Lind et al, 1998). EXTL2
encodes an α 1,4-N-acetylhexosaminyltransferase that initiates HS
synthesis (Kitigawa et al, 1999). It is not implicated in HME, but has
been assigned to a chromosome region (1p11–p12) that is frequently
rearranged in sporadic cancer. Although the function of EXTL3 is
unknown, it is a candidate gene for the breast cancer locus on chro-
mosome 8p12–p22 and is mutated in 25% of early colorectal carci-
noma cell lines (Arai et al, 1999). In HME HS is assumed to regulate
a critical signalling pathway(s) in bone formation. In mice, EXT1
and EXT2 become restricted to skeletal elements during embryonic
development and their expression overlaps with Indian hedgehog,
which controls chondrocyte maturation (Stickens et al, 2000). The
HME story has fuelled interest in HS biosynthesis but also provided
several puzzles. In particular, why is the disease phenotype
restricted to bone, given the ubiquitous distribution of HS on cell
surfaces and in the ECM? One possibility is that currently unidenti-
fied genes may substitute for EXT1 and EXT2 functions in non-
osteogenic tissues (see below). 
The contribution of other enzymes involved in HS biosynthesis to
tumorigenesis has not been determined. Like the EXTs, the NDSTs,
6OSTs and 3OSTs (Figure 2) belong to multigene families (Selleck,
2000 and references therein). At least 4 distinct mammalian
isoforms of NDST, 3 6OSTs and 7 3OSTs have been identified and
shown to exhibit tissue-specific expression patterns. Preliminary
studies have demonstrated a correlation between HS structure and
isoform expression (Habuchi et al, 2000). The possibility of differ-
ential isoform expression in tumour tissues suggests the potential for
selective manipulation of signalling pathways for therapeutic gain.
For example, wild-type CHO cells spontaneously form tumours
when injected subcutaneously into athymic mice, and inhibition of
2-O-sulfation of HS abolishes bFGF binding resulting in smaller
tumours that are poorly vascularised (Esko, 1999). 
RESEARCH TOOLS 
Progress in our understanding of HSPGs has been hampered by the
lack of suitable tools to examine structure activity relationships but
recent years have witnessed significant advances in the availability of
such analytical techniques. Developmental genetic studies, particu-
larly in Drosophila, and manipulation of genes encoding biosynthetic
enzymes for HS have accelerated functional analyses of HSPGs. The
availability of recombinant exoenzymes, used in the treatment of
inherited mucopolysaccharidoses has inspired various techniques
sensitive enough to reveal the exact order and composition of mono-
saccharides within an HS sequence of interest akin to DNA or
peptide sequencing (Merry et al, 1999). Immunohistochemistry and
in situ hybridisation studies of HSPG core proteins within human
tumour sections have generated expression maps to correlate with
clinical data. However, structural information about HS in situ has
been limited due to the poor immunogenicity of HS and difficulty in
raising antibodies. The application of phage display technology has
generated new antibodies that may be capable of discriminating
distinct HS epitopes (van Kuppevelt et al, 1998). One caveat in the
interpretation of immunohistochemical studies of HSPGs is the influ-
ence of cellular origin and context on the structure and function of
these molecules. To address this, a novel functional assay has been
designed to detect the ability of HSPGs to form signalling complexes
in situ (Chang et al, 2000). Tissues of interest are preincubated with
bFGF (that binds to HS) then exposed to a soluble cognate-signalling
receptor (FR) linked to alkaline phosphatase (AP). FR-AP is
detectable if the HSPG–bFGF interaction favours recuritment of the
soluble receptor into a trimolecular (signalling) complex. This tech-
nique has revealed that extracellular matrix HSPGs such as perlecan
can bind bFGF strongly, but fail to incorporate FR-AP, suggesting an
inhibitory role. Preliminary findings using this technique in ovarian
cancer sections also suggest that some bFGF–HS complexes are
biologically inactive (J Davies, unpublished observation). The assay
is suitable for adaptation to recognise other signalling pathways e.g.
VEGF, and isolation of HSPG isoforms present in active versus inac-
tive signalling complexes should provide novel insights into growth
factor regulation by HSPGs in different tissues. 
GLYCO-ONCOLOGY: THE CHALLENGE 
HSPGs play pivotal roles in cellular control, co-ordinating and
directing appropriate responses to multiple ligands. The natural
mechanisms regulating their activities may be exploited by cancer
cells that liberate varying cocktails of growth factors, cytokines,
proteases and heparanase(s). Furthermore, evidence from 2 inherited
human syndromes supports a direct role for HSPGs in tumorigenesis.
The clinical success of heparin has prompted the development of
Figure 3 Radiograph of an exostosis arising from the juxtaepiphyseal
region of the femur in a 2 year old. Exostoses are benign osteochondromas
that are at risk of malignant transformation. Photograph from Dr J Clayton
Smith, Department of Medical Genetics, St Mary’s Hospital, Manchester, with
kind permission 1098 FH Blackhall et al
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HSPG ‘mimics’ to antagonise HB growth factors and heparanase(s).
However, in view of the tissue-specific and multifaceted interactions
of these molecules, caution is required to avoid promoting unwanted
ligand interactions caused by HS(PG) mimics that lack sufficient
specificity. The present challenge is to combine the recent advances
in genetic, molecular, biochemical and immunological tools to
further unravel the roles of HSPGs in cancer, and to characterise
novel targets for ‘safe’ therapeutic control. To this end, the biosyn-
thetic machinery for HS may hold the key to selectively modulate
critical HSPG-dependent signalling pathways. 
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